#USA #Cambridge #biotechnology #Nona Biosciences #Dr. Josh Xiao

Nona Biosciences Appoints Dr. Josh Xiao as Chief Scientific Officer

Nona Biosciences, a prominent name in the global biotechnology landscape, has announced the strategic appointment of Dr. Josh Xiao as its new Chief Scientific Officer (CSO). This significant move comes as part of Nona’s ongoing commitment to biotherapeutic innovation through advanced technology platforms.

Based in both the US and China, Dr. Xiao will report directly to Dr. Di Hong, Nona's CEO. His primary responsibilities include leading the evolution of Nona's global scientific strategy and overseeing technological advancements, particularly focusing on the Hu-mAtrIxTM platform, an AI-driven tool for drug discovery. Under his leadership, Nona aims to enhance its competitive edge and foster collaboration within the ecosystem of biotechnology.

Having amassed over 25 years of rich experience in drug discovery and biopharmaceutical leadership, Dr. Xiao's credentials are impressive. His academic background includes a Ph.D. in Biochemistry from Louisiana State University, followed by a postdoctoral tenure at Columbia University. Prior to joining Nona, he was an entrepreneur in residence at RA Ventures — a healthcare-focused incubator — and a co-founder of Starfish Medicines. His career has spanned leadership roles at major companies such as Amgen and Millennium Pharmaceuticals, giving him extensive experience in target discovery, therapeutic development, and regulatory filings.

In his new role, Dr. Xiao will not only be responsible for spearheading Nona's scientific strategy but will also guide project leaders globally to establish a robust capability development framework. This initiative aims to enhance project execution, deepen insights into partner needs, and streamline the integration of various platform resources. According to Dr. Di Hong, this seasoned expertise in drug discovery and team leadership is essential for steering Nona towards its growth trajectory in the biotechnology field.

Reflecting on his new position, Dr. Xiao expressed enthusiasm about joining Nona’s team at such a critical juncture. He acknowledged Nona’s pioneering endeavors in developing fully human antibodies using proprietary platforms, marking them as leaders in the biotherapeutics arena. His vision is to bolster these technology platforms and help partners succeed in their therapeutic innovations.

Nona Biosciences is recognized for its impressive proprietary technologies that generate fully human monoclonal antibodies. Their Harbour Mice® platforms provide clinical validation, opening doors to various therapeutic modalities including bispecific antibodies and CAR-T therapies. Furthermore, integrating their unique platforms like NonaCarFxTM and Hu-mAtrIxTM underlines their commitment to advancing drug development from preliminary ideas to clinical advances.

As Nona continues to push the boundaries of biotherapeutic development, the strategic insights and direction provided by Dr. Xiao will undoubtedly steer the company towards achieving unprecedented heights in medical innovation and partner collaboration. Looking ahead, Nona Biosciences is set to revolutionize the landscape of biotherapeutics, enriching lives globally with innovative solutions. For more detailed information on Nona's offerings, visit Nona's official website.